A discussion of the latest developments in the medical and dietary management of IBD.

Video Content:

00:00 Intro/Welcome
04:27 Discussing Benefits, Risks of Treatment, & Uncontrolled Disease with Patients.
05:08 Starting with Crohn’s Disease
06:23 CD Clinical Symptoms May Not Correlate with Intestinal Inflammation
08:10 Skyrizi (Risankizumab) for Crohn’s Disease: An IL23 Inhibitor
10:09 Skyrizi (Clinical Remission at Week 52)
13:19 Skyrizi (Fortify AEs)
16:16 Skyrizi (Frequency of Dosing Convenience)
16:36 New Drugs For Ulcerative Colitis: Zeposia & Rinvoq
17:42 Disease Progression Necessitates Changes in UC Treatment
19:29 Ulcerative Colitis: Sigmoidoscopy/Colonoscopy: What Does Inflammation Look Like?
20:17 MAYO Endoscopy Subscores
21:59 Zeposia (Ozanimod): A S1P Modulator
24:11 Zeposia (Symptomatic Response & Remission)
25:22 Zeposia (Control is Possible Without the use of Corticosteroids)
25:22 Zeposia (Drug Discontinuation Rates Less Than Placebo)
28:03 Rinvoq (Upadacitinib) for Ulcerative Colitis: A JakKinase Inhibitor
29:44 Rinvoq (PatientReported Outcomes Data by Day)
30:50 Rinvoq (Clinical Remission at Week 8)
32:45 Rinvoq (AEs of Special Interest)
34:57 Treatment Summary
38:13 Advances in the Role of Diet in IBD
41:53 Fiber: Friend or Foe?
44:40 Eternal Nutrition
46:10 Recommended Dietary Patterns in CD & UC
48:16 Specific Carbohydrate Diet (SCD)
49:52 Mediterranean Diet
52:04 Nutritional Takeaways
53:09 Q&A